BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 16720200)

  • 1. Beyond detectable minimal residual disease in chronic lymphocytic leukemia.
    Hillmen P
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S23-8. PubMed ID: 16720200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
    Robak T
    Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
    Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
    J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Robak T
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE; Rai KR; O'Brien S
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
    Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
    Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of minimal residual disease in chronic lymphocytic leukemia.
    Schweighofer CD; Hallek M; Wendtner CM
    Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
    Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
    Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
    Kharfan-Dabaja MA; Fahed R; Hussein M; Santos ES
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1799-815. PubMed ID: 17970639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody combinations in CLL: evolving strategies.
    Faderl S; O'Brien S; Keating MJ
    Best Pract Res Clin Haematol; 2006; 19(4):781-93. PubMed ID: 16997183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab: what is the secret to safe therapy?
    Elter T; Hallek M; Montillo M
    Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
    Rai KR
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S15-22. PubMed ID: 16720199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
    Schweighofer CD; Ritgen M; Eichhorst BF; Busch R; Abenhardt W; Kneba M; Hallek M; Wendtner CM
    Br J Haematol; 2009 Jan; 144(1):95-8. PubMed ID: 19016732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
    J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
    Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy of chronic lymphocytic leukemia.
    Mavromatis B; Cheson BD
    J Clin Oncol; 2003 May; 21(9):1874-81. PubMed ID: 12721266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.